IRVINE, CA, Jan. 10, 2018 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce that it has established a Construction Project Management Team (CPMT) to work closely with its Security Team (CBISST) to coordinate and support the Company’s aggressive growth initiatives, which include the establishment of a number of CBIS Pharmacies in Los Angeles and eventually nationwide, as well as CBIS Medical Centers that will facilitate the Company’s direct interaction with its patients.
“The CBIS CPMT will have overall planning, coordination, and control responsibilities for CBIS projects from initiation to completion,” stated Mr. Raymond C. Dabney, CBIS’ President, CEO, and Co-founder. “CPMT will manage and help ensure the functional and financial viability of our projects. With the construction industry experts we have on our CPMT, as well as the experienced security professionals on our CBISST, we expect our plans to build and expand CBIS Pharmacies and Medical Centers throughout California and the U.S. to be streamlined, secure, and completed on-time and within budget.”
As part of its activities, the CBISST will develop a Facility Security Plan (FSP). This plan is a critical component of CBIS’ security program. The guidelines for CBIS’ FSP are based on recognized industry best practices and provide broad recommendations for the protection of CBIS facilities and CBIS employees, contractors, patients and visitors. CBIS’ FSP will be generally applicable to all buildings and facilities operated and occupied by CBIS employees, including but not limited to:
• Buildings and facilities owned or leased by CBIS;
• CBIS leased rooms or suites within privately owned buildings;
• Stand-alone CBIS facilities;
• CBIS campuses, research laboratories, medical centers, offices and pharmacies; and
• Individual facilities on CBIS campuses and special-use facilities where appropriate.
The CBIS Construction Project Management Team and the CBIS Security Team will work hand in hand to deliver robust secure environments wherever CBIS is operating. The Security Team will conduct various threat assessments, which is the process of identifying or evaluating entities, actions, or occurrences (natural or man-made) that possess or indicate the potential to harm or destroy CBIS assets. The threat assessment will consider the full spectrum of threats (i.e., natural, criminal, terrorist, accidental, etc.) for a given facility/location. Threat data can be derived from various resources including security organizations, intelligence community reports and assessments, as well as state and local authorities. The CBIS Security Team will periodically produce a Design-Basis Threat Report (DBT) that will be used to identify a broad range of threats to CBIS facilities and will be updated regularly based on threat trends and data provided. For example, the crime rates in areas surrounding CBIS facilities will be assessed as an indicator of the type of criminal activity that may put CBIS facilities at risk.
The Risk Management Process for CBIS’ facilities will include an Interagency Security Committee (ISC) Standard that is the key starting point for the development of a Facility Security Plan (FSP). Once the FSP is applied, other critical elements will be added to make the plan a more robust document. The Facility Profile for each CBIS asset will be fully-considered in the development of each FSP. Profile factors will include:
• Type of facility (e.g., single or multi-story, campus, mixed-use, etc.);
• Population (e.g., single or multi-tenant, care center, visitors, etc.);
• Mission and critical functions conducted at the facility (e.g., dispensary operations, patient administration, operations center, patient information center, continuity of operations [COOP] site, etc.);
• Utilities (e.g., power, water, gas, communications, etc.); and
• The most current facility diagrams, construction documents and specifications.
“The formation of CBIS’ Construction Project Management and Security Teams give our Company important access to construction and security experts,” stated Mr. Dabney. “This will help the Company implement our expansion plans and establish CBIS Pharmacies and Medical Centers in California and throughout the U.S. We expect this important development to support our planned revenue growth in 2018 and to create value for our shareholders.”
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company's reports filed with the Securities and Exchange Commission.
Cannabis Science, Inc.
Dr. Allen Herman
Chief Medical Officer (CMO)
Cannabis Science, Inc.
Mr. Raymond C. Dabney
President & CEO, Co-Founder